Effects of levosimendan on left ventricular functional remodelling and exercise intolerance: A tissue Doppler study

Journal of International Medical Research

Volumn 33, Issue 4, 2005, Pages 397-405

  Kasikcioglu, Hulya A ^a,c   Unal, S ^a   Tartan, Z ^a   Uyarel, H ^a   Okmen, E ^a   Kasikcioglu, E ^b   Cam, N ^a  

^a Siyami Ersek Cardiovascular Surgery Center   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

^c NONE   (Turkey)

Author keywords

Exercise; Heart failure; Inotropic agents; Tissue Doppler imaging

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LEVOSIMENDAN; PLACEBO;

ADULT; AGED; ARTICLE; BOLUS INJECTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOPPLER ECHOCARDIOGRAPHY; EXERCISE; EXERCISE TOLERANCE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CONTRACTILE FORCE; HEART MUSCLE CONTRACTILITY; HEART VENTRICLE REMODELING; HUMAN; HYPOKINESIA; MITRAL VALVE; RANDOMIZED CONTROLLED TRIAL;

EID: 23044438641     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000503300405     Document Type: Article

References (25)

1. Remme WJ, Swedberg K: Taskforce for the Diagnosis and Treatment of Chronic Heart Failure, European Society of Cardiology: Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001; 22: 1527-1560.
2. McAlister FA, Teo KK: The management of congestive heart failure. Postgrad Med J 1997; 73: 194-200.
3. Francis GS: Neurohumoral activation and progression of heart failure: hypothetical and clinical considerations. J Cardiovasc Pharmacol 1998; 32 (Suppl 1): S16-S21.
4. Steering Committee and Membership of the Advisory Council To Improve Outcomes Nationwide in Heart Failure (ACTION HF): Consensus recommendations for the management of chronic heart failure. Am J Cardiol 1999; 83: 1A-38A.
5. Figgitt DP, Gillies PS, Goa KL: Levosimendan. Drugs 2001; 61: 613-627.
6. Sutherland GR, Stewart MJ, Groundstroem KW, Moran CM, Fleming A, Guell-Peris FJ, et al: Color Doppler myocardial imaging: a new technique for the assessment of myocardial function. J Am Soc Echocardiogr 1994; 7: 441-458.
7. Gulciti V, Katz WE, Follansbee WP, Gorcsan J: Mitral annular descent velocity by tissue Doppler echocardiography as an index of global left ventricular function. Am J Cardiol 1996; 77: 979-984.
8. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, et al: Recommendations for quantitation of the left ventricular by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989; 2: 358-367.
9. Wahr DW, Wang YS, Schiller NB: Left ventricular volumes determined by two-dimensional echocardiography in a normal adult population. J Am Coll Cardiol 1983; 1: 863-868.
10. Kasikcioglu E, Oflaz H, Akhan H, Kayserilioglu A, Mercanoglu F, Umman B, et al: Left ventricular remodeling and aortic distensibility in elite power athletes. Heart Vessels 2004; 19: 183-188.
11. Guyatt GH, Sullivan MJ, Thompson PJ, Fallen EL, Pugsley SO, Taylor DW, et al: The six minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J 1985; 132: 919-923.
12. Nieminen MS, Akkila J, Hasenfuss G, Kleber FX, Lehtonen LA, Mitrovic V, et al: Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol 2000; 36: 1903-1912.
13. Coats AJS: Positive inotropy for acute heart failure complicating myocardial infarction. Eur Heart J 2002; 23: 1405-1406.
14. Slawsky MT, Colucci WS, Gottlieb SS, Greenberg BH, Haeusslein E, Hare J, et al: Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation 2000; 102: 2222-2227.
15. Bowman P, Haikala H, Paul R: Levosimendan, a calcium sensitizer in cardiac muscle, induces relaxation in coronary smooth muscle through calcium desensitization. J Pharmacol Exp Ther 1999; 288: 316-325.
16. Gruhn N, Nielsen-Kudsk JE, Theilgaard S, Bang L, Olesen SP, Aldershvile J: Coronary vasorelaxant effect of levosimendan, a new inodilator with calcium-sensitizing properties. J Cardiovasc Pharmacol 1998; 31: 741-749.
17. Belardinelli R, Georgiou D, Cianci G, Purcaro A: Randomized, controlled trial of long-term moderate exercise training in chronic heart failure: effects on functional capacity, quality of life, and clinical outcome. Circulation 1999; 99: 1173-1182.
18. Yip G, Wang M, Zhang Y, Fung JW, Ho PY, Sanderson JE: Left ventricular long axis function in diastolic heart failure is reduced in both diastole and systole: time for a redefinition? Heart 2002; 87: 121-125.
19. Witte KK, Nikitin NP, De Silva R, Cleland JG, Clark AL: Exercise capacity and cardiac function assessed by tissue Doppler imaging in chronic heart failure. Heart 2004; 90: 1144-1150.
20. Sohn DW, Chai IH, Lee DJ, Kim HC, Kim HS, Oh BH, et al: Assessment of mitral annulus velocity by Doppler tissue imaging in the evaluation of left ventricular diastolic function. J Am Coll Cardiol 1997; 30: 474-480.
21. Nagueh SF, Middleton KJ, Kopelen HA, Zoghbi WA, Quinones MA: Doppler tissue imaging: a noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures. J Am Coll Cardiol 1997; 30: 1527-1533.
22. Rump AF, Acar D, Klaus W: A quantitative comparison of functional and anti-ischaemic effects of the phosphodiesterase inhibitors, amrinone, milrinone and levosimendan in rabbit isolated hearts. Br J Pharmacol 1994; 112: 757-762.
23. Hasenfuss G, Pieske B, Castell M, Kretschmann B, Maier LS, Just H: Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation 1998; 98: 2141-2147.
24. 2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart. Circ Res 1995; 77: 107-113.
25. Pagel PS, McGough MF, Hettrick DA, Lowe D, Tessmer JP, Jamali IN, et al: Levosimendan enhances left ventricular systolic and diastolic function in conscious dogs with pacing-induced cardiomyopathy. J Cardiovasc Pharmacol 1997; 29: 563-573.